Cargando…

Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report

Advanced hepatocellular carcinoma (HCC) is a highly lethal disease, mainly due to the late stage at diagnosis and its rapid progression. Although patients with advanced HCC can choose targeted therapy or chemotherapy, overall, the treatment response rate is extremely low and the average survival tim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Chenxi, Shao, Jie, Dong, Yanbing, Xu, Qiuping, Zou, Zhengyun, Chen, Fangjun, Yan, Jing, Liu, Juan, Li, Shuangshuang, Liu, Baorui, Shen, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315135/ https://www.ncbi.nlm.nih.gov/pubmed/34326839 http://dx.doi.org/10.3389/fimmu.2021.685126

Ejemplares similares

Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report
por: Shao, Jie, et al.
Publicado: (2022)

Individualised adjuvant immunotherapy with neoantigen‐reactive T cells for gastric signet‐ring cell carcinoma
por: Ding, Naiqing, et al.
Publicado: (2023)

The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody
por: Liu, Chenxi, et al.
Publicado: (2022)

Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer
por: Liu, Qin, et al.
Publicado: (2022)

Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer (Adv. Sci. 1/2023)
por: Liu, Qin, et al.
Publicado: (2023)

Mutation-Derived Neoantigens for Cancer Immunotherapy
por: Castle, John C., et al.
Publicado: (2019)

Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy
por: Guo, Yugang, et al.
Publicado: (2018)

Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
por: Roerden, Malte, et al.
Publicado: (2019)

Neoantigen: A New Breakthrough in Tumor Immunotherapy
por: Zhang, Zheying, et al.
Publicado: (2021)

Disappearance of bone metastases in chemotherapy-resistant gastric cancer treated with antigen peptide-pulsed dendritic cell-activated cytotoxic T lymphocyte immunotherapy: A case report
por: Du, Juan, et al.
Publicado: (2018)

T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy
por: Sim, Malcolm J. W., et al.
Publicado: (2022)

The Efficacy and Safety of Hypofractionated Radiation Therapy With Tomotherapy for Advanced or Recurrent Hepatocellular Carcinoma
por: Shen, Jie, et al.
Publicado: (2021)

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
por: Efremova, Mirjana, et al.
Publicado: (2017)

The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy
por: Karpanen, Terhi, et al.
Publicado: (2017)

Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
por: Wirth, Thomas C., et al.
Publicado: (2017)

New techniques: a roadmap for the development of HCC immunotherapy
por: Jiang, Dizhi, et al.
Publicado: (2023)

Cancer immunotherapy‐targeted glypican‐3 or neoantigens
por: Shimizu, Yasuhiro, et al.
Publicado: (2018)

A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China
por: Zhu, Sihui, et al.
Publicado: (2021)

Identification of a novel gene signature for the prediction of recurrence in HCC patients by machine learning of genome-wide databases
por: Shen, Jie, et al.
Publicado: (2020)

The Role of Neoantigens in Cancer Immunotherapy
por: Zhu, Yueting, et al.
Publicado: (2021)

Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy
por: Shou, Jiawei, et al.
Publicado: (2022)

Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives
por: Chen, Xiaotong, et al.
Publicado: (2020)

Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens
por: Kiyotani, Kazuma, et al.
Publicado: (2018)

Recent advances in neoantigen vaccines for treating non‐small cell lung cancer
por: Su, Shu, et al.
Publicado: (2023)

Neoantigen‐reactive T cell: An emerging role in adoptive cellular immunotherapy
por: Zhu, Yicheng, et al.
Publicado: (2021)

Personalized cancer neoantigen vaccines come of age
por: Chu, Yanhong, et al.
Publicado: (2018)

Determinants for Neoantigen Identification
por: Garcia-Garijo, Andrea, et al.
Publicado: (2019)

Neoantigens in Hematologic Malignancies
por: Biernacki, Melinda A., et al.
Publicado: (2020)

Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1
por: Wu, Di, et al.
Publicado: (2020)

Neoantigens and their potential applications in tumor immunotherapy
por: Fang, Xianzhu, et al.
Publicado: (2022)

Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation
por: Seliktar-Ofir, Sivan, et al.
Publicado: (2017)

A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment
por: Chen, Zheling, et al.
Publicado: (2021)

The Neoantigen Landscape of Mycosis Fungoides
por: Sivanand, Arunima, et al.
Publicado: (2020)

Editorial: The Clinical Application of Neoantigens
por: Zhou, Jian-Guo, et al.
Publicado: (2022)

NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy
por: Xia, Jiaqi, et al.
Publicado: (2021)

Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy
por: Davis, Lindy, et al.
Publicado: (2021)

Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report
por: Zeng, Yongyi, et al.
Publicado: (2020)

High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy
por: Mauriello, Angela, et al.
Publicado: (2019)

Identifying neoantigens for use in immunotherapy
por: Hutchison, Sharon, et al.
Publicado: (2018)

Targeting neoantigens for cancer immunotherapy
por: Zhao, Xuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k1nr9e28sp8ke1o9inhj6mo1q0